TickerFacts.

Aardvark Therapeutics, Inc. (AARD): Cash & Equivalents

Annual figures by period end, from SEC filings.

$47.05M
As of 2025-12-31
$73.85M
As of 2026-06-30
$61.64M2024-12-31: $61.64M2025-12-31: $47.05M$47.05M
2024-12-31 Cash & Equivalents (USD) 2025-12-31
Period endedCash & EquivalentsChange YoYSource filing
2025-12-31$47.05M-23.7%2026-03-23, Balance as of period end
2024-12-31$61.64Mn/a2026-03-23, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCash & EquivalentsChange YoY
Aardvark Therapeutics, Inc. (AARD)2025-12-31$47.05M-23.7%
Abbott Laboratories (ABT)2025-12-31$8.52B+11.9%
Bristol Myers Squibb Co (BMY)2025-12-31$10.21B-1.3%
TherapeuticsMD, Inc. (TXMD)2024-12-31$5.06M+16.9%
Eli Lilly & Co (LLY)2025-12-31$7.27B+122.4%
Pfizer Inc (PFE)2025-12-31$1.14B+9.5%
Johnson & Johnson (JNJ)2025-12-28$19.71B-18.2%
Nature's Sunshine Products Inc (NATR)2025-12-31$93.89M+10.9%
Merck & Co., Inc. (MRK)2025-12-31$14.56B+10.0%

Compare AARD, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗